Phase 2 Rheumatoid Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to give their written agreement to take part, understand what the study involves, and commit to following the study procedures throughout.
- People aged 18 to 70 years (inclusive) at the time of signing the consent form.
- People who have been diagnosed with rheumatoid arthritis (RA) according to recognised international classification guidelines, with a functional level rated as Class I, II, or III (meaning some ability to carry out daily activities is still present) (confirm with trial site).
- People whose RA is moderately to severely active, based on specific counts of tender and swollen joints (at least 6 of each) and elevated inflammation markers in blood tests at the time of screening and at the start of the study.
Who may not be able to join:
- People with a known allergy to any ingredient in the study drug (GenSci120), or who have a history of allergic reactions to any medications, substances, or foods.
- People who have another autoimmune or autoinflammatory condition in addition to RA — such as psoriatic arthritis, lupus, inflammatory bowel disease, ankylosing spondylitis, multiple sclerosis, or primary Sjögren's syndrome, among others (secondary Sjögren's syndrome is excluded from this restriction — confirm with trial site).
- People who have another joint condition, such as severe osteoarthritis, that could make it difficult to accurately assess RA disease activity, as determined by the study doctors.
- People who have a history of lymphoma or other disorders affecting the lymph system, or who currently show signs such as abnormally enlarged lymph nodes or an enlarged liver or spleen.
- People who currently have, or have previously had, a cancer diagnosis.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhanguo LI, Doctor, Peking University People's Hospital
Phone: +86 18201085833
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of participants achieving the American College of Rheumatology 20% improvement criteria (ACR20) for disease activity assessment in RA from baseline after 14 weeks of administration
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.